SEC Form 4 · accession 0000899243-18-026060
Ocugen, Inc. · OCGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lynne E Kelley
Officer — Chief Medical Officer
Period of report
Oct 1, 2018
Accepted (ET)
Oct 3, 2018 · 5:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001372299
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $2.21 | Oct 1, 2018 | D | 200,000 | D | — | Jul 30, 2028 | Common Stock | 200,000 | 0 | D |
| Employee Stock Option (Right to Buy)F2 | $0.568 | Oct 1, 2018 | A | 200,000 | A | — | Jul 30, 2028 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on October 1, 2018. Pursuant to the Option Repricing, the exercise price of each "Relevant Option" (any stock option awarded by the Issuer under it 2012 Equity Incentive Plan or 2013 Equity Incentive Plan with an exercise price greater than $ 0.75628 per share held by current service providers other than the non-employee members of the Issuer's board of directors) has been amended to reduce such exercise price to $0.568, which was the closing price of a share of the Issuer's common stock reported on The Nasdaq Capital Market on October 1, 2018. There have been no other changes to the terms of the Relevant Options.
- F2The stock option was originally granted to the Reporting Person on July 31, 2018. This option vests over four (4) years of service following July 31, 2018, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service and in thirty-six (36) equal monthly installments thereafter.